Warning: The NCBI web site requires JavaScript to function. more...
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.
Sanders RW, van Anken E, Nabatov AA, Liscaljet IM, Bontjer I, Eggink D, Melchers M, Busser E, Dankers MM, Groot F, Braakman I, Berkhout B, Paxton WA.
Retrovirology. 2008 Jan 31;5:10.
Related citations
Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R.
Virology. 2003 Sep 1;313(2):387-400.
Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site.
Herrera C, Spenlehauer C, Fung MS, Burton DR, Beddows S, Moore JP.
J Virol. 2003 Jan;77(2):1084-91.
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP.
J Virol. 2002 Jul;76(14):7293-305.
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR.
J Virol. 2002 Jul;76(14):7306-21.
The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC.
J Virol. 2005 Jun;79(11):6909-17.
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR.
J Virol. 2003 Jan;77(1):642-58.
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.
Sterjovski J, Churchill MJ, Ellett A, Gray LR, Roche MJ, Dunfee RL, Purcell DF, Saksena N, Wang B, Sonza S, Wesselingh SL, Karlsson I, Fenyo EM, Gabuzda D, Cunningham AL, Gorry PR.
Retrovirology. 2007 Dec 12;4:89.
Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding.
Berkower I, Patel C, Ni Y, Virnik K, Xiang Z, Spadaccini A.
Virology. 2008 Aug 1;377(2):330-8. Epub 2008 Jun 2.
Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
Pantophlet R, Wilson IA, Burton DR.
Protein Eng Des Sel. 2004 Oct;17(10):749-58. Epub 2004 Nov 12.
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.
Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.
An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.
Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee FH, Montefiori D, Smith DF, Doms RW, Geng Y.
J Virol. 2008 Jul;82(13):6447-57. Epub 2008 Apr 23.
Structural definition of a conserved neutralization epitope on HIV-1 gp120.
Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD.
Nature. 2007 Feb 15;445(7129):732-7.
Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P, Gan J, Wu YQ, Zhang MY, Dimitrov DS, Ji X.
J Mol Biol. 2006 Mar 17;357(1):82-99. Epub 2006 Jan 9.
Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding.
Hong PW, Flummerfelt KB, de Parseval A, Gurney K, Elder JH, Lee B.
J Virol. 2002 Dec;76(24):12855-65.
Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop.
Duenas-Decamp MJ, Peters P, Burton D, Clapham PR.
J Virol. 2008 Jun;82(12):5807-14. Epub 2008 Apr 2.
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.
Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL.
J Virol. 2008 Jan;82(2):638-51. Epub 2007 Oct 24.
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR.
J Virol. 2011 Sep;85(17):8954-67. Epub 2011 Jun 29.
Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.
Yuan W, Bazick J, Sodroski J.
J Virol. 2006 Jul;80(14):6725-37.
N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
Gray ES, Moore PL, Pantophlet RA, Morris L.
J Virol. 2007 Oct;81(19):10769-76. Epub 2007 Jul 18.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on